Payment overview · 2025
General Payments
$269.23
10 reported records · 10 companies
Healthcare provider profile · identity verified
Charles D Borum, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NATCHEZ, MS · NPI 1417042979
Verified facts
What the public records show
CMS Open Payments records show Charles D Borum, M.D. received $269.23 in general payments during 2025 across 10 reported records.
Phathom Pharmaceuticals, Inc. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.01 | 30.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.43 | 11.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.55 | 8.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.93 | 8.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.48 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.19 | 7.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.16 | 6.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.16 | 6.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.42 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.90 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $269.23 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $83.01 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 705 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 678 | 183 |
| Potassium Chloride | Potassium Chloride | 623 | 156 |
| Gabapentin | Gabapentin | 560 | 130 |
| Furosemide | Furosemide | 559 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 136 |
| Meloxicam | Meloxicam | 355 | 86 |
| Trazodone Hcl | Trazodone Hcl | 342 | 76 |
| Metformin Hcl | Metformin Hcl | 335 | 81 |
| Sertraline Hcl | Sertraline Hcl | 323 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 91 |
| Eliquis | Apixaban | 317 | 55 |
| Memantine Hcl | Memantine Hcl | 315 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 267 | 56 |
| Carvedilol | Carvedilol | 255 | 64 |
| Losartan Potassium | Losartan Potassium | 253 | 58 |
| Tramadol Hcl | Tramadol Hcl | 242 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 60 |
| Xarelto | Rivaroxaban | 222 | 25 |
| Donepezil Hcl | Donepezil Hcl | 216 | 38 |
| Lisinopril | Lisinopril | 214 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 57 |
| Prednisone | Prednisone | 212 | 110 |
| Alprazolam | Alprazolam | 205 | 57 |
| Divalproex Sodium | Divalproex Sodium | 197 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 58 |
| Omeprazole | Omeprazole | 189 | 66 |
| Levetiracetam | Levetiracetam | 177 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 48 |
| Simvastatin | Simvastatin | 167 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 26 |
| Allopurinol | Allopurinol | 148 | 46 |
| Buspirone Hcl | Buspirone Hcl | 143 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 29 |
| Ozempic | Semaglutide | 128 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 48 |
| Azithromycin | Azithromycin | 108 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 43 |
| Spironolactone | Spironolactone | 103 | 26 |
| Lorazepam | Lorazepam | 101 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 34 |
| Olanzapine | Olanzapine | 97 | 15 |
| Mirtazapine | Mirtazapine | 96 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 22 |
| Famotidine | Famotidine | 95 | 19 |
| Lovastatin | Lovastatin | 95 | 34 |
| Jardiance | Empagliflozin | 94 | 23 |
| Risperidone | Risperidone | 94 | 16 |
| Linzess | Linaclotide | 89 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 88 | 11 |
| Entresto | Sacubitril/Valsartan | 87 | 11 |
| Sucralfate | Sucralfate | 87 | 21 |
| Trulicity | Dulaglutide | 86 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 26 |
| Pregabalin | Pregabalin | 85 | 20 |
| Aripiprazole | Aripiprazole | 82 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 23 |
| Bumetanide | Bumetanide | 77 | 17 |
| Haloperidol | Haloperidol | 77 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 22 |
| Farxiga | Dapagliflozin Propanediol | 76 | 12 |
| Ibuprofen | Ibuprofen | 73 | 27 |
| Rivastigmine | Rivastigmine | 73 | 16 |
| Baclofen | Baclofen | 72 | 14 |
| Bupropion Xl | Bupropion Hcl | 72 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 62 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 14 |
| Scopolamine | Scopolamine | 60 | suppressed |
| Fluconazole | Fluconazole | 59 | 34 |
| Alendronate Sodium | Alendronate Sodium | 58 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Latanoprost | Latanoprost | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 55 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 25 |
| Digoxin | Digoxin | 54 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | 21 |
| Atenolol | Atenolol | 52 | 22 |
| Clonidine Hcl | Clonidine Hcl | 51 | 21 |
| Diazepam | Diazepam | 51 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 48 | 11 |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 16 |
| Novolin R Flexpen | Insulin Regular, Human | 47 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 46 | 22 |
| Naproxen | Naproxen | 46 | 25 |
| Nifedipine Er | Nifedipine | 46 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 29 |
| Clonidine | Clonidine | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Glipizide | Glipizide | 44 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 41 | 20 |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 21 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 38 | suppressed |
| Lubiprostone | Lubiprostone | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 11 |
| Glimepiride | Glimepiride | 37 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 14 |
| Gemtesa | Vibegron | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 17 |
| Temazepam | Temazepam | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | 15 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Humulin R | Insulin Regular, Human | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 11 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 16 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Ertapenem | Ertapenem Sodium | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 13 |
| Metolazone | Metolazone | 30 | 12 |
| Dutasteride | Dutasteride | 29 | suppressed |
| Estradiol | Estradiol | 29 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 14 |
| Phenytoin | Phenytoin | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | 12 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Finasteride | Finasteride | 21 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 20 | 19 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 19 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Daptomycin-0.9% Nacl | Daptomycin In 0.9 % Sod Chlor | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Sulindac | Sulindac | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Anastrozole | Anastrozole | 13 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $269.23 · 10 records | Phathom Pharmaceuticals, Inc. | BREZTRI, CAPLYTA, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, QULIPTA, UBRELVY, VERQUVO, VOQUEZNA, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error